Carlsbad, CA — October 6, 2025 — Leads & Copy — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) announced leadership and governance changes to bolster its executive team and financial transparency, supporting its strategic growth phase.
Effective October 2, 2025, Jerry (Jiawei) Wang became Co-Chief Executive Officer, and Koti Meka was appointed Chief Financial Officer. Wang, Global President and founding team member of Faraday Future, raised over $3 billion in funding and led its IPO in 2021. Meka was also the CFO of Faraday Future. Prior to Faraday Future, Meka worked at Ford Motor Company from July 2002 to February 2016 in cost optimization, product development finance and corporate finance.
Qualigen’s Board of Directors appointed three new members following a private placement on September 29, 2025: Kevin Chen (Independent Director), Chad Chen, and Jay Sheng. Sheng is Chairman of the Audit Committee, with Graydon Bensler and Chad Chen as members. Chad Chen, Kevin Chen, and Jay Sheng are on the Nominating & Corporate Governance and Compensation Committees.
Mr. Sheng is a board member of Faraday Future and Head of Operations & Finance Director of FF Global Partners LLC. Previously, he was Deputy Managing Director of China Aviation Fuel (Europe) Limited. Mr. Kevin Chen is Chief Economist and Chief Investment Officer of Horizon Financial and holds board positions at CurrenC Group, Australian Oilseeds Investments, Scage Future and Capitan Investment Ltd. Mr. Chad Chen is a board member of Faraday Future and a partner at Yoka | Smith, LLP.
Cody Price, Robert Lim, and Campbell Becher resigned from the Board, with Becher remaining as President. The resignations were amicable.
The Audit Committee approved Macias Gini & O’Connell LLP (“MGO”) as the new independent registered public accounting firm, replacing WhitumSmith+Brown, PC (“Withum”), effective October 1, 2025. MGO also audits Faraday Future.
Kevin Richardson, the Co-CEO of the Company, stated that the changes mark an important step forward for Qualigen Therapeutics.
Investor Relations Department
Qualigen Therapeutics, Inc.
5857 Owens Avenue, Suite 300, Carlsbad, CA 92008
Tel: +1 (760) 452-8111
Email: info@qualigeninc.com
Source: Qualigen Therapeutics, Inc.
